Search results
Mavenclad and cost: Reducing long-term drug costs and more
Medical News Today· 14 hours agoMavenclad (cladribine) is a brand-name oral tablet that’s prescribed for certain types of multiple...
Senator slams drugmaker for seeming to skirt pledge to cap inhaler cost
The Hill via AOL· 6 hours agoDrug manufacturing giant GSK is subverting its pledge to lower the price of its brand-name inhaler...
Lawsuit accuses Boehringer Ingelheim of false patent listings
Hartford Business Journal· 11 hours agoIngelheim Pharmaceuticals Inc. of manipulating the U.S. patent and drug approval system to “exclude ...
These Are the Drugs America Is Running Short On
247wallst.com· 3 days agoDrug shortages in America are the result of supply line challenges, profit-based operations, and company closures.
Sen. Hassan slams GlaxoSmithKline over cost of asthma inhalers
New Hampshire Union Leader· 1 day agoLess than two months after GlaxoSmithKline pledged...Sen. Maggie Hassan, D-N.H., is accusing the ...
Wisconsin high school football coach unable to get chemo due to shortage dies at 60
NBC News via Yahoo News· 2 days ago“A number of firms are going either out of business, or they’re having quality problems because...
Bausch Health (BHC) Q1 Earnings and Revenues Miss Estimates
Zacks· 21 hours agoThis quarterly report represents an earnings surprise of -21.33%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. , which belongs ...
FTC Warns ‘Junk Patents’ Could Make Drugs Like Ozempic Pricier—Here’s How
Forbes· 3 days agoThe FTC sent warning letters to 10 pharmaceutical companies—including Novo Nordisk, AstraZeneca,...
Novo’s Blockbuster Ozempic Among FTC’s Latest Patent Targets
Bloomberg Law· 2 days agoOzempic and Victoza are among 20 branded drugs the Federal Trade Commission is targeting as it challenges more than 300 “junk patent listings” in the FDA’s registry of approved drugs in an effort ...
FTC Targets ‘Junk’ Patent Listings on Ozempic and Other Drugs
The Wall Street Journal· 2 days agoHaving one generic competitor for a brand-name drug cuts prices by about 40%, the FDA has said. The...